• 1
    González-Martín AJ, Calvo E, Bover I, et al. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann Oncol. 2005; 16: 749-755.
  • 2
    Pfisterer J, Plante M, Vergote I, et al.; AGO-OVAR; NCIC CTG; EORTC GCG. Gemcitabine plus carboplatin compared to carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006; 24: 4699-4707.
  • 3
    Parmar MKB, Ledermann JA, Colombo N, et al.; ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003; 361: 2099-2106.
  • 4
    Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist. 1999; 4: 87-94.
  • 5
    Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Gynecol Oncol. 2004; 9: 67-73.
  • 6
    Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist. 2000; 5: 26-35.
  • 7
    Guéritte-Voegelein F, Guénard D, Lavelle F, Le Goff MT, Mangatal L, Potier P. Relationships between the structure of Taxol analogs and their antimitotic activity. J Med Chem. 1991; 34: 992-998.
  • 8
    Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P, André S. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol. 1995; 22( 2 suppl 4 ): 3-16.
  • 9
    Francis P, Schneider J, Hann L, et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol. 1994; 12: 2301-2308.
  • 10
    Kavanagh JJ, Kudelka AP, de Leon CG, et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res. 1996; 2: 837-842.
  • 11
    Rose PG, Blessing JA, Ball HG, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003; 88: 130-135.
  • 12
    Kaye SB, Piccart M, Aapro M, Francis P, Kavanagh J. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview. Eur J Cancer. 1997; 33: 2167-2170.
  • 13
    Aapro M, Pujade-Lauraine E, Lhomme C, et al. Phase II study of taxotere in ovarian cancer [Abstract]. Ann Oncol. 1994; 5( suppl 5): 202.
  • 14
    Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol. 2000; 19: 1901-1905.
  • 15
    Vasey PA, Jayson GC, Gordon A, et al.; Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004; 96: 1682-1691.
  • 16
    Tabernero J, Climent MA, Lluch A, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol. 2004; 15: 1358-1365.
  • 17
    Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000; 18: 1212-1219.
  • 18
    Hainsworth JD, Burris HA 3rd, Yardley DA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: A Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol. 2001; 19: 3500-3505.
  • 19
    Hainsworth JD, Vokes EE. Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer. Semin Oncol. 2001; 28: 22-27.
  • 20
    Tomiak E, Piccart MJ, Kerger J, et al. Phase-I Study of docetaxel administered as a 1-kour intravenous-infusion on a weekly basis. J Clin Oncol. 1994; 12: 1458-1467.
  • 21
    Loeffler TM, Freund W, Hausamen TU. Activity of weekly Taxotere (TXT) in patients with metastatic breast cancer. Proc Am Soc Clin Oncol. 1998; 17: 113a (abstract 435).
  • 22
    Climent MA, Ruiz A, Llombart-Cussac A, et al. Weekly docetaxel in patients with advanced malignancies. Toxicity profile and activity results. Proc Am Soc Clin Oncol. 1999; 18: 119a (abstract 453).
  • 23
    Kushner DM, Connor JP, Sanchez F, et al.; Wisconsin Oncology Network. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. Gynecol Oncol. 2007; 105: 358-364.
  • 24
    Chahine GY, Nasr FL, Kattan JG, et al. Phase II trial of weekly docetaxel and carboplatin as first line chemotherapy in advanced or metastatic non small cell lung cancer (NSCLC). J Clin Oncol. 2005; 23: 16s (abstr 7330).
  • 25
    Kaira K, Tsuchiya S, Sunaga N, et al. A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer. Am J Clin Oncol. 2007; 30: 51-56.
  • 26
    Fish LS, Lewis BE. Quality of life issues in the management of ovarian cancer. Semin Oncol. 1999; 26: 32-39.
  • 27
    Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al. Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol. 2001; 19: 1809-1817.
  • 28
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
  • 29
    Rustin GJ, Nelstrop AE, Bentzen SM, Piccart MJ, Bertelsen K. Use of tumour markers in monitoring the course of ovarian cancer. Ann Oncol. 1999; 10( suppl 1): 21-27.
  • 30
    Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001; 19: 3312-3322.
  • 31
    Chow S-C, Shao J, Wang H. Sample Size Calculations in Clinical Research. New York, NY: Marcel Dekker; 2003.
  • 32
    Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982; 38: 29-41.
  • 33
    Fairclough DL, Peterson HF, Cella D, Bonomi P. Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials. Stat Med. 1998; 17: 781-796.
  • 34
    Fayers PM, Machin D. Quality of Life: Assessment, Analysis and Interpretation. Hoboken, NJ: John Wiley & Sons; 2000.
  • 35
    Verbeke GG, Molenberghs G. Linear Mixed Models in Practice: A SAS-Oriented Approach. New York, NY: Springer; 1997.
  • 36
    Tinker AV, Gebski V. Fitzharris B, et al. Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel - ANZGOG 02-01. Gynecol Oncol. 2007; 104: 647-653.
  • 37
    Berkenblit A, Seiden MV, Matulonis UA, et al. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol. 2004; 95: 624-631.
  • 38
    Baker SD, Zhao M, Lee CK, et al. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res. 2004; 10: 1976-1983.
  • 39
    Camps C, Massuti B, Jiménez A, et al.; Spanish Lung Cancer Group. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol. 2006; 17: 467-472.
  • 40
    Gridelli C, Gallo C, Di Maio M, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 Study. Br J Cancer. 2004; 91: 1996-2004.
  • 41
    Rivera E, Mejia JA, Arun BK, et al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer. 2007; 112: 1455-1461.
  • 42
    Schuette W, Nagel S, Blankenburg T, et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol. 2005; 23: 8389-8395.
  • 43
    Di Maio M, Perrone F, Chiodini P, et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non small-cell lung cancer. J Clin Oncol. 2007; 25: 1377-1382.
  • 44
    Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A gynecologic oncology group study. J Clin Oncol. 2000; 18: 106-115.
  • 45
    International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002; 360: 505-515.
  • 46
    Bast RC, Thigpen JT, Arbuck SG, et al. Clinical trial endpoints in ovarian cancer: Report of an FDA/ASCO/AACR public workshop. Gynecol Oncol. 2007; 107: 173-176.
  • 47
    Cantù MG, Buda A, Parma G, et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens J Clin Oncol. 2002; 20: 1232-1237.